Overview

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Watson Pharmaceuticals
Treatments:
Silodosin